VANCOUVER, BC, November 17th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company,  announced today that Company Co-Founder and Chief Medical Officer David Berd, MD, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 taking place November 30-December 2, 2021 in San Diego.

Dr. Berd will discuss the role of immunotherapeutic vaccines in cancer, the potential of haptenized autologous tumor cell vaccines for treating a range of cancer types, and BioVaxys’ advancement of haptenized viral antigens as a platform for addressing SARS-CoV-2, SARS-CoV-1, and other sarbecoviruses.

Details of the presentation are as follows:

Title:        Haptenized Vaccines for Viral Diseases & Cancer

When:    December 1, 2021 @ 17:10

Where:     Lowes Coronado Hotel, San Diego, CA

“BioVaxys is honored to be invited to speak at the World Vaccine & Immunotherapy Congress alongside a prestigious group of vaccine and immunology experts. We look forward to sharing how we are leveraging our haptenized protein platform to create autologous cancer immunotherapies synergistic with checkpoint inhibitors, as well as protein-based vaccines for infectious disease,” said Dr. Berd.

A medical oncologist, Dr. Berd has a life-long record of clinical research in medical oncology and cancer immunotherapy. For more than 20 years, he was a professor of medicine at Thomas Jefferson University, where he conducted clinical research on melanoma vaccines. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals in addition to myriad editorials, reviews, and abstracts. He has 10 issued cancer vaccines patents.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. ( is a British Columbia-registered, clinical-stage immunotherapy company developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has multiple issued U.S. patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).


Signed “James Passin”

James Passin, CEO

+1 646 452 7054

Cautionary Statements Regarding Forward Looking Information 

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys’ vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. 

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys’ vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.


Media Contact: 

Gina Cestari
6 Degrees Public Relations
+1 917 797 7904